Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicolini, F.
Right arrow Articles by Hayette, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicolini, F.
Right arrow Articles by Hayette, S
Haematologica, Vol 91, Issue 1, 137-138
Copyright © 2006 by Ferrata Storti Foundation

Letter

The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib

FE Nicolini, K Chabane, JM Cayuela, P Rousselot, X Thomas, and S Hayette

Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosine kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.


This article has been cited by other articles:


Home page
 haematolHome page
T. Ernst, J. Hoffmann, P. Erben, B. Hanfstein, A. Leitner, R. Hehlmann, A. Hochhaus, and M. C. Muller
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Haematologica, September 1, 2008; 93(9): 1389 - 1393.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.